New Gene-Immuno combo aims to keep lung cancer at bay
NCT ID NCT05703971
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tests a new gene therapy (quaratusugene ozeplasmid) combined with an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if this combination can delay cancer progression. About 62 adults whose cancer has shrunk or stabilized after initial treatment will participate. This is an early-phase trial, so safety and the best dose are also being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gabrail Cancer Center Research
RECRUITINGCanton, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwest Cancer Specialists, P.C.
RECRUITINGPortland, Oregon, 97213-2982, United States
Contact
Contact Email: •••••@•••••
-
Northwest Cancer Specialists, P.C.
RECRUITINGPortland, Oregon, 97227, United States
Contact
Contact Email: •••••@•••••
-
Northwest Cancer Specialists, P.C.
RECRUITINGTigard, Oregon, 97223, United States
Contact
Contact Email: •••••@•••••
-
Northwest Cancer Specialists, P.C.
TERMINATEDVancouver, Washington, 98684, United States
-
Oncology_Hematology Care Clinical Trials, LLC
RECRUITINGCincinnati, Ohio, 45211, United States
Contact
Contact Email: •••••@•••••
-
Oncology_Hematology Care Clinical Trials, LLC
RECRUITINGCincinnati, Ohio, 45236, United States
Contact
Contact Email: •••••@•••••
-
Oncology_Hematology Care Clinical Trials, LLC
RECRUITINGCincinnati, Ohio, 45242, United States
Contact
Contact Email: •••••@•••••
-
Oncology_Hematology Care Clinical Trials, LLC
RECRUITINGCincinnati, Ohio, 45245, United States
Contact
Contact Email: •••••@•••••
-
Oncology_Hematology Care Clinical Trials, LLC
RECRUITINGFairfield, Ohio, 45014, United States
Contact
Contact Email: •••••@•••••
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rocky Mountain Cancer Centers, LLP
RECRUITINGLone Tree, Colorado, 80124, United States
Contact Email: •••••@•••••
Contact
-
Texas Oncology - DFW
RECRUITINGDallas, Texas, 75246, United States
Contact Email: •••••@•••••
Contact
-
Texas Oncology - Northeast Texas
RECRUITINGTyler, Texas, 75702, United States
Contact
Contact Email: •••••@•••••
-
Virginia Cancer Specialists, PC
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Email: •••••@•••••
-
Washington University School of Medicine - Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Willamette Valley Cancer Institute (Oregon)
RECRUITINGEugene, Oregon, 97401, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.